What is the share price of Venus Remedies Ltd (VENUSREM) today?
The share price of VENUSREM as on 24th July 2026 is ₹1649. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Venus Remedies Ltd (VENUSREM) share?
The past returns of Venus Remedies Ltd (VENUSREM) share are- Past 1 week: -6.31%
- Past 1 month: -7.20%
- Past 3 months: 73.65%
- Past 6 months: 120.41%
- Past 1 year: 223.49%
- Past 3 years: 498.98%
- Past 5 years: 268.45%
What are the peers or stocks similar to Venus Remedies Ltd (VENUSREM)?
The peers or stocks similar to Venus Remedies Ltd (VENUSREM) include:What is the dividend yield % of Venus Remedies Ltd (VENUSREM) share?
The current dividend yield of Venus Remedies Ltd (VENUSREM) is 0.61.What is the market cap of Venus Remedies Ltd (VENUSREM) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Venus Remedies Ltd (VENUSREM) is ₹2204.22 Cr as of 24th July 2026.What is the 52 week high and low of Venus Remedies Ltd (VENUSREM) share?
The 52-week high of Venus Remedies Ltd (VENUSREM) is ₹2044.30 and the 52-week low is ₹424.What is the PE and PB ratio of Venus Remedies Ltd (VENUSREM) stock?
The P/E (price-to-earnings) ratio of Venus Remedies Ltd (VENUSREM) is 21.44. The P/B (price-to-book) ratio is 3.93.Which sector does Venus Remedies Ltd (VENUSREM) belong to?
Venus Remedies Ltd (VENUSREM) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Venus Remedies Ltd (VENUSREM) shares?
You can directly buy Venus Remedies Ltd (VENUSREM) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Venus Remedies Ltd
VENUSREM Share Price
NSE₹1,649.000.40% (-6.60)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
VENUSREM Stock Scorecard
Performance
HighThe creamy layer - amongst the top performing stocks
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
VENUSREM Performance & Key Metrics
VENUSREM Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 18.97 | 3.93 | 0.61% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.74 | 5.90 | 0.53% |
VENUSREM Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
VENUSREM Company Profile
Venus Remedies Limited is engaged in pharmaceutical product manufacturing business. The Company provides formulations and manufactures dosage injectables.
SUNPHARMA
PE Ratio
40.57
40.57
1Y Return
14.72%
14.72%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
87.23
87.23
1Y Return
40.96%
40.96%
Buy Reco %
78.57
78.57
CIPLA
PE Ratio
29.38
29.38
1Y Return
5.20%
5.20%
Buy Reco %
66.67
66.67
ZYDUSLIFE
PE Ratio
21.94
21.94
1Y Return
14.15%
14.15%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.32
20.32
1Y Return
22.10%
22.10%
Buy Reco %
55.56
55.56
VENUSREM Forecast
VENUSREM Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
VENUSREM
VENUSREM
Income
Balance Sheet
Cash Flow
Quarterly Normal View
VENUSREM Income Statement
VENUSREM Income Statement
Quarterly Normal View
| Quarter | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | jun 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 199.08 | 110.20 | 178.03 | 188.80 | 201.73 | 140.59 | 194.46 | 182.78 | 264.35 | 181.48 | ||||||||||
Operating & Other expenses | 175.69 | 97.35 | 162.53 | 158.50 | 165.97 | 121.80 | 161.79 | 142.74 | 195.98 | 144.67 | ||||||||||
EBITDA | 23.39 | 12.85 | 15.50 | 30.30 | 35.76 | 18.79 | 32.67 | 40.04 | 68.37 | 36.81 | ||||||||||
| Depreciation/Amortization | 5.91 | 5.98 | 6.41 | 5.41 | 4.71 | 6.18 | 6.17 | 6.56 | 6.75 | 6.77 | ||||||||||
| PBIT | 17.48 | 6.87 | 9.09 | 24.89 | 31.05 | 12.61 | 26.50 | 33.48 | 61.62 | 30.04 | ||||||||||
| Interest & Other Items | 0.02 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | ||||||||||
| PBT | 17.46 | 6.85 | 9.07 | 24.88 | 31.04 | 12.60 | 26.49 | 33.47 | 61.61 | 30.04 | ||||||||||
| Taxes & Other Items | 6.95 | 5.63 | 5.56 | 5.28 | 10.04 | 3.00 | 6.36 | 7.89 | 14.11 | 7.07 | ||||||||||
| Net Income | 10.51 | 1.22 | 3.51 | 19.60 | 21.00 | 9.60 | 20.13 | 25.58 | 47.50 | 22.97 | ||||||||||
| EPS | 7.86 | 0.92 | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.53 | 17.18 |
VENUSREM Company Updates
VENUSREM Stock Peers
VENUSREM Past Performance & Peer Comparison
VENUSREM Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Venus Remedies Ltd | 21.44 | 3.93 | 0.61% |
| Sun Pharmaceutical Industries Ltd | 40.57 | 5.55 | 0.82% |
| Torrent Pharmaceuticals Ltd | 87.23 | 10.73 | 0.68% |
| Cipla Ltd | 29.38 | 3.30 | 0.92% |
VENUSREM Stock Price Comparison
Compare VENUSREM with any stock or ETFCompare VENUSREM with any stock or ETF
VENUSREM
VENUSREM Holdings
VENUSREM Shareholdings
VENUSREM Promoter Holdings Trend
VENUSREM Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
VENUSREM Institutional Holdings Trend
VENUSREM Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
VENUSREM Shareholding Pattern
VENUSREM Shareholding Pattern
VENUSREM Shareholding History
VENUSREM Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing VENUSREM stock
smallcases containing VENUSREM stock
Looks like this stock is not in any smallcase yet.
VENUSREM Events
VENUSREM Events
VENUSREM Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
VENUSREM Dividend Trend
No dividend trend available
VENUSREM Upcoming Dividends
VENUSREM Upcoming Dividends
No upcoming dividends are available
VENUSREM Past Dividends
VENUSREM Past Dividends
Cash Dividend
Ex DateEx DateSep 23, 2013
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 23, 2013
Cash Dividend
Ex DateEx DateSep 20, 2012
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 20, 2012
Cash Dividend
Ex DateEx DateSep 22, 2011
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 22, 2011
Cash Dividend
Ex DateEx DateSep 23, 2010
Final
Final | Div/Share: ₹3.00
Dividend/Share
₹3.00
Ex DateEx Date
Sep 23, 2010
VENUSREM Stock News & Opinions
VENUSREM Stock News & Opinions
Articles & Videos
Earnings
Earnings
Venus Remedies consolidated net profit rises 139.27% in the June 2026 quarterNet profit of Venus Remedies rose 139.27% to Rs 22.97 crore in the quarter ended June 2026 as against Rs 9.60 crore during the previous quarter ended June 2025. Sales rose 30.38% to Rs 178.86 crore in the quarter ended June 2026 as against Rs 137.18 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales178.86137.18 30 OPM %19.1211.21 - PBDT36.8118.78 96 PBT30.0412.60 138 NP22.979.60 139 Powered by Capital Market - Live
5 days agoCapital Market - Live
Corporate
Corporate
Venus Remedies to discuss resultsVenus Remedies will hold a meeting of the Board of Directors of the Company on 20 July 2026.
2 weeks agoCapital Market - Live
Corporate
Corporate
Venus Remedies to convene AGMVenus Remedies announced that the 37th Annual General Meeting(AGM) of the company will be held on 20 August 2026.
1 month agoCapital Market - Live
Corporate
Corporate
Board of Venus Remedies recommends final dividendVenus Remedies announced that the Board of Directors of the Company at its meeting held on 26 May 2026, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 100%) , subject to the approval of the shareholders.
1 month agoCapital Market - Live
Earnings
Earnings
Venus Remedies consolidated net profit rises 126.19% in the March 2026 quarterNet profit of Venus Remedies rose 126.19% to Rs 47.50 crore in the quarter ended March 2026 as against Rs 21.00 crore during the previous quarter ended March 2025. Sales rose 33.05% to Rs 259.40 crore in the quarter ended March 2026 as against Rs 194.97 crore during the previous quarter ended March 2025. For the full year,net profit rose 126.81% to Rs 102.79 crore in the year ended March 2026 as against Rs 45.32 crore during the previous year ended March 2025. Sales rose 17.88% to Rs 769.60 crore in the year ended March 2026 as against Rs 652.89 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales259.40194.97 33 769.60652.89 18 OPM %24.4514.87 -19.1410.50 - PBDT68.3635.75 91 159.8284.42 89 PBT61.6131.04 98 134.1661.91 117 NP47.5021.00 126 102.7945.32 127 Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Earnings
Venus Remedies standalone net profit rises 193.78% in the March 2026 quarterNet profit of Venus Remedies rose 193.78% to Rs 43.45 crore in the quarter ended March 2026 as against Rs 14.79 crore during the previous quarter ended March 2025. Sales rose 31.65% to Rs 259.01 crore in the quarter ended March 2026 as against Rs 196.74 crore during the previous quarter ended March 2025. For the full year,net profit rose 88.98% to Rs 99.31 crore in the year ended March 2026 as against Rs 52.55 crore during the previous year ended March 2025. Sales rose 19.28% to Rs 768.73 crore in the year ended March 2026 as against Rs 644.47 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales259.01196.74 32 768.73644.47 19 OPM %22.9512.83 -18.7211.64 - PBDT64.0829.33 118 155.3790.77 71 PBT57.5724.84 132 130.6869.15 89 NP43.4514.79 194 99.3152.55 89 Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Corporate
Venus Remedies receives Saudi FDA approval for PlerixaforVenus Remedies has received Marketing Authorization from the Saudi Food and Drug Authority (SFDA) for Plerixafor. This is the first Marketing Authorization Venus Remedies has secured for Plerixafor anywhere in the world. It is also a deliberate step in the company's move toward complex, higher-value specialty injectables in oncology and critical care, replacing reliance on commodity injectable volumes with diifferentiated therapies in regulated markets. Plerixafor is a hematopoietic stem cell mobilizer used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant.
2 months agoCapital Market - Live
Corporate
Corporate
Venus Remedies to discuss resultsVenus Remedies will hold a meeting of the Board of Directors of the Company on 26 May 2026.
2 months agoCapital Market - Live
Earnings
Earnings
Venus Remedies consolidated net profit rises 30.51% in the December 2025 quarterNet profit of Venus Remedies rose 30.51% to Rs 25.58 crore in the quarter ended December 2025 as against Rs 19.60 crore during the previous quarter ended December 2024. Sales rose 2.12% to Rs 180.26 crore in the quarter ended December 2025 as against Rs 176.52 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales180.26176.52 2 OPM %20.8110.21 - PBDT40.0320.38 96 PBT33.4714.97 124 NP25.5819.60 31 Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Corporate
Venus Remedies to hold board meetingVenus Remedies will hold a meeting of the Board of Directors of the Company on 29 January 2026.Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 5.43%, vs industry avg of 12.48%
Over the last 5 years, market share decreased from 0.21% to 0.15%
Over the last 5 years, net income has grown at a yearly rate of 10.73%, vs industry avg of 10.55%